Results 251 to 260 of about 64,427 (282)

Keratoacanthomas associated with imatinib mesylate

Acta Oncologica, 2010
To the Editor,Imatinib mesylate, an orally available inhibitor of constitutively activated BCR-ABL tyrosine kinase, platelet-derived growth factor receptor (PDGFR) alpha and beta, and the c-kit rec...
Klaus J. Busam, Yevgeniy Balagula, Jedd D. Wolchok, Richard D. Carvajal, Patricia L. Myskowski   +4 more
openaire   +2 more sources

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Journal of Clinical Oncology, 2008
PURPOSE To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus a high dose (400 mg twice ...
C. Blanke, C. Rankin, G. Demetri, C. Ryan, M. von Mehren, R. Benjamin, A. Raymond, V. Bramwell, L. Baker, R. Maki, Michael S Tanaka, J. Hecht, M. Heinrich, C. D. Fletcher, J. Crowley, E. Borden   +15 more
semanticscholar   +1 more source

Imatinib mesylate in polycythemia vera

Blood, 2004
In the September 15, 2003, issue of Blood, [1][1] Oehler et al describe imatinib mesylate inhibition of the autonomous in vitro proliferation of peripheral blood– and bone marrow–derived polycythemia vera (PV) erythroid burst-forming units (BFU-Es).
Richard T. Silver, Jerry L. Spivak
openaire   +2 more sources

Imatinib Mesylate in Chronic Myeloid Leukemia

Current Stem Cell Research & Therapy, 2007
Chronic myeloid leukemia has become a paradigm for the discovery of target therapeutic approaches in the field of onco-hematology. Recognition of the tyrosine kinase activity of the p210Bcr-Abl oncoprotein led to the development of compounds targeting against BCR-ABL and then controlling the leukemic proliferation.
Angelo Michele Carella, Enrica Lerma
openaire   +2 more sources

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis

American Journal of Hematology, 2003
AbstractImatinib mesylate targets the adenosine triphosphate (ATP)‐binding sites of the protein tyrosine kinase domains associated with Bcr‐abl, the platelet‐derived growth factor (PDGF) and c‐kit. In idiopathic myelofibrosis (IMF) PDGF is considered to be one of the growth factors responsible for the development of bone marrow fibrosis.
B A Jensen, Henrik Birgens, Per Boye Hansen, Ole Weiss Bjerrum, Marianne Hamilton Therkildsen, Hans Carl Hasselbalch, Nielsaage Tøffner Clausen, Elisabeth Ralfkiaer   +7 more
openaire   +3 more sources

Imatinib mesylate in children and adolescents with cancer

Pediatric Blood & Cancer, 2010
AbstractImatinib is an inhibitor of theBCR–ABLfusion gene product that characterizes chronic myeloid leukemia (CML), and of the related tyrosine kinases c‐KIT and platelet‐derived growth factor (PDGF) receptor. The drug is now included as front‐line therapy for CML and Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and ...
openaire   +3 more sources

Imatinib mesylate: an innovation in treatment of autoimmune diseases.

Recent Patents on Inflammation & Allergy Drug Discovery, 2013
Imatinib mesylate is a selective protein tyrosine kinase inhibitor, which can inhibit BCR/Abl, PDGF-R, c-KIT, c-fms, TCR/Abl, Lck, FLT-3 and MAPKs activities on various cell types.
G. Azizi, A. Mirshafiey
semanticscholar   +1 more source

Imatinib Mesylate (Gleevec)

2015
Great strides had been made in the war against cancer with chemotherapy even before the emergence of protein kinase inhibitors. For instance, prior to vinblastine (1, Velban) became available in 1964 for the treatment of lymphoma, the diagnosis of Hodgkin’s disease (a cancer of the lymph nodes) was virtually a death sentence.
openaire   +1 more source

Antitumor activity of imatinib mesylate in neuroblastoma xenografts

Cancer Letters, 2005
Imatinib mesylate has antitumor activity in vitro and in vivo against neuroblastoma cell lines and xenografts characterized by a different expression of receptor tyrosine kinases. In this article, we report that imatinib tumor concentration can be independent of the administered dose and does not correlate with the antitumor effect. In xenografts, high-
Josef Brueggen, Carlo Dominici, Carlo Dominici, Carlo Dominici, Riccardo Riccardi, Daniela Meco, Marco Gessi, Anna Riccardi, Tiziana Servidei   +8 more
openaire   +4 more sources

Imatinib Mesylate for Cerebral Langerhans'-Cell Histiocytosis

New England Journal of Medicine, 2004
To the Editor: Langerhans'-cell histiocytosis (LCH) is a rare disorder characterized by tissue infiltrates of CD1a+ Langerhans' cells, eosinophils, neutrophils, macrophages, and lymphocytes.
Montella L, INSABATO, LUIGI, PALMIERI, GIOVANNELLA   +2 more
openaire   +3 more sources